BioPharmSignal logoBioPharmSignal

Biotech News

Veradigm Extends Stockholder Rights Plan

Veradigm (MDRX)VeradigmCompany update

CHICAGO --(BUSINESS WIRE)--Feb. 2, 2026-- Veradigm® (OTCMKTS: MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, today announced that its Board of Directors (the “Board”) has approved an amendment to extend the Company’s existing Stockholder Rights Plan to

Related news

MDRXVeradigm2026-08-17 12:01 EST

Veradigm to Participate in Two Upcoming Investor Conferences

MDRXVeradigm2026-05-26 20:10 EST

Veradigm Files 2023 and 2024 Form 10-K

View all latest news

Veradigm

Veradigm is a healthcare information and analytics company focused on software, data, and workflow tools for providers and life-sciences customers. Its business is more about information infrastructure than therapeutic innovation.

Recent company news

MDRXVeradigm2026-08-17 12:01 EST

Veradigm to Participate in Two Upcoming Investor Conferences

MDRXVeradigm2026-05-26 20:10 EST

Veradigm Files 2023 and 2024 Form 10-K

MDRXVeradigm2026-05-26 12:01 EST

Veradigm to Release Business Update May 26th and Host Investor Call May 27th

MDRXVeradigm2026-05-06 20:01 EST

Veradigm Launches Health Network Architecture to Level the Playing Field for Independent Practices

MDRXVeradigm2026-05-06 12:01 EST

Veradigm Survey: Independent Practices Rely on Technology to Stay Independent

Stock data

Close
4.97 USD
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States